PATENT CLAIM ANALYSIS

Application Number: 16194909
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["424", "722000"]

Abstract:
Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT 2B  agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.

Claim (Index 28):
The method of  claim 21 , wherein the refractory epilepsy is Dravet syndrome.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 98.0
- Lexical Diversity: 1.59574
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16193812', '14447253', '13887014', '15003161', '14447303']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7931957297699509
- 35 USC 102 Novelty (BERT): 0.6500506016074823
- Combined Prediction Score: 0.778881216953704
- Mean Citation Score: 456.984562
- Max Citation Score: 808.15515
- Similarity Product: 566.3001205178887

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test